For Media: UK Press Releases

This page contains resources intended for journalists only. For media enquiries about our press releases please contact

Your Selection
Clear All
Bayer UKI launches first digital patient support package in diabetic kidney disease
Bayer invests 250 million USD in new cell therapy manufacturing facility in the U.S.
Scottish Medicines Consortium (SMC) recommends two Bayer cancer treatments for use within NHSScotland
NICE recommends Bayer’s NUBEQA®▼ (darolutamide) + ADT in combination with docetaxel
NICE publishes guidance recommending Bayer’s Kerendia®▼(finerenone)
NICE gives green light for Stivarga® (regorafenib) in metastatic colorectal cancer (mCRC)
Bayer receives acceptance of Kerendia®▼ (finerenone) by Scottish Medicines Consortium (SMC)
NUBEQA®▼ (darolutamide) + ADT in combination with docetaxel licenced by MHRA